Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 26th, 2026

LECO_Weekly-Healthcare-News_10-26-2026Download

Healthcare News and Deals

  1. EQT Private Equity has agreed to acquire QIAGEN N.V. (NYSE: QGEN) in a recommended all-cash voluntary public takeover offer valuing the molecular testing company at approximately $12.1 billion enterprise value. EQT XI, through Crown NL Bidco, is offering €46.50 per share in cash — a 40.3% premium to the unaffected XETRA close on July 8. Including about $1.1 billion of net debt, the deal values QIAGEN at roughly $12.1 billion. The Dutch tools and diagnostics company has been the subject of takeover talk for years. Both boards are recommending the offer after a strategic review. Affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board are co-investing. QIAGEN will keep its name and brand. (Link)
  2. HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform HealthSpan Partners has agreed to buy Surgery Partners (NASDAQ: SGRY), the Bain Capital-backed operator of ambulatory surgery centers and surgical hospitals. Reports put the value at about $6 billion, including roughly $3.5 billion of debt, with Bain keeping its nearly 40% stake. Surgery Partners runs more than 170 surgical facilities across 30 states. HealthSpan is an affiliate of Bon Secours Mercy Health and is picking up a large outpatient surgical footprint. (Link)
  3. AEA Investors-Backed American Oncology Network Agrees to a $2.4 Billion Sale to Cencora, Adding 350+ Community Oncology Providers to Cencora’s Physician MSO Platform. Cencora (NYSE: COR) signed a definitive agreement on October 20 to buy the roughly 96% of Fort Myers-based American Oncology Network (OTCQX: AONC) it does not already own. The deal values AON at $2.4 billion enterprise value — $2.3 billion at closing plus up to $100 million in contingent value rights. Some AON holders can roll up to 25% of their equity; if they do, Cencora expects to write a check of about $1.7 billion for 75% ownership. AON brings more than 350 providers across 21 states and adds 12 new states to Cencora’s MSO footprint. Clinical decisions stay with AON physicians. It is Cencora’s fourth physician-platform deal since January 2025, after Retina Consultants of America, OneOncology and the EyeSouth retina business. (Link)
  4. Kohlberg Is Buying Alcanza Clinical Research from Martis Capital for Approximately $800–850 Million Axios Pro reported that Kohlberg is buying Alcanza Clinical Research from Martis Capital for between $800 million and $850 million. Alcanza is a clinical research site network founded in 2021 that focuses on inclusive trial access and runs more than 25 sites across the U.S. and Puerto Rico. It does Phase I–IV studies for pharma sponsors and CROs. (Link)
  5. Blackstone- and TPG-Backed Hologic Signs a Definitive Agreement to Acquire Reveal Genomics, Maker of the HER2DX Breast Cancer Test Hologic, now owned by Blackstone and TPG after a take-private of up to about $18.3 billion, has agreed to buy Barcelona-based Reveal Genomics. Reveal makes the HER2DX genomic test, which helps guide therapy for HER2-positive breast cancer. The test sits alongside Hologic’s Breast Cancer Index assay and adds another treatment-selection tool. It is the first clear sign that the new owners plan to use Hologic as a buy-and-build platform in women’s-health diagnostics. (Link)
  6. Apogem Capital Leads a Minority Investment in Revelstoke-Backed Family Care Center, Returning Capital to LPs While Revelstoke Stays In Family Care Center, the outpatient mental health platform backed by Revelstoke Capital Partners, closed a minority equity sale led by Apogem Capital. Revelstoke is staying in. Since Revelstoke partnered with founder Dr. Chuck Weber in December 2020, the company has grown entirely by opening new clinics — from four locations in one state to more than 50 across five states. It now has more than 800 providers and expects nearly 1 million treatment sessions in 2026, across therapy, psychiatry, TMS and intensive outpatient programs. Revelstoke described the deal as a way to return capital to its LPs without selling the whole company. Jefferies advised Family Care Center. (Link)
  7. EQT-Backed Sagility Agrees to Acquire Tennessee’s Chirok Health for Up to $32.35 Million, Adding Clinical Documentation Integrity and Coding Capability Sagility (US) Holdings, a subsidiary of the EQT-backed healthcare BPO Sagility, signed a definitive agreement on October 21 to buy Chirok Health, a Tennessee firm that does revenue cycle management, clinical documentation integrity and medical coding. The price is $20 million at closing plus up to $12.35 million in earnout. Chirok did about $9 million of revenue in 2025. The deal adds provider-side capability for Sagility. (Link)
  8. Altaris-Backed Tegria Acquires CloudWave, Its First Add-On Since the Providence Carve-Out, to Build a Healthcare Cybersecurity and Hosting Platform Tegria, the healthcare consulting, managed services and technology company that Altaris carved out of Providence in January 2026, bought CloudWave. CloudWave does cloud hosting, managed IT and cybersecurity (LECO sold BlueOrange to Cloudwave in 2025) only for healthcare clients, and it runs a dedicated 24/7 security operations center. CloudWave CEO Erik Littlejohn becomes president of Tegria’s Enterprise Technical Solutions. It is Tegria’s first add-on since the carve-out. (Link)
  9. Renovus Capital Partners Strikes a Deal for Chicagoland Orthopedic Home Health Provider Aspire Home Health Care Renovus Capital Partners, the Philadelphia-area lower-middle-market firm that already owns Louisiana home health and hospice platform Superior Health Holdings, has agreed to buy Aspire Home Health Care. Aspire was founded in 2013 and is based in Morton Grove, Illinois. It provides skilled nursing and therapy at home for patients recovering from orthopedic procedures, surgeries and complex conditions. The deal gives Renovus a post-surgical home health business in the Chicago market. (Link)
  10. Kohlberg-Backed Trinity Life Sciences Acquires Verix to Add AI-Driven Commercial Execution Tools for Pharma Trinity, the life sciences commercialization advisory and analytics firm that Kohlberg & Company has owned since 2021, bought Verix. Verix’s Tovana platform uses AI to give pharmacommercial teams next-best-action recommendations, patient finding and HCP targeting, and it is used by large pharma companies. The deal moves Trinity from strategy and insights into software that field teams actually use day to day. (Link)
  11. New Harbor Capital’s LGM Pharma Acquires New Jersey Contract Lab Sannova Analytical LGM Pharma, the API sourcing and CDMO platform that New Harbor Capital has majority-owned since 2017, bought Sannova Analytical. Sannova is a Somerset, New Jersey contract lab that does bioanalytical and CMC testing for pharma and biotech companies. It had been backed by SFW Capital Partners since 2022. The deal adds an East Coast testing operation to LGM’s development and manufacturing services. (Link)
  12. Blue Sea Capital-Backed One Physics Adds Two West Coast Medical Physics Firms, Expanding into the Pacific Northwest and Northern California One Physics, the largest outsourced medical physics company in North America, is buying two firms that do diagnostic medical physics and radiation safety work in the Pacific Northwest and Northern California. Blue Sea Capital has backed One Physics since 2019 and moved it into a single-asset continuation vehicle earlier this year. The company has already done 22 acquisitions and serves more than 7,000 client sites in 45+ states with over 210 physicists. (Link)
  13. HCAP Partners- and Salt Creek-Backed Real Diagnostics Adds Saliva-Based Oral Health Testing Firm SimplyTest Real Diagnostics (RealDx), the Maryland-based high-complexity molecular lab that Salt Creek Capital and HCAP Partners bought in September 2025, acquired SimplyTest. SimplyTest makes saliva-based tests, including its PERIO test, that identify bacteria linked to gum disease, and it sells to dentists and functional medicine practices. The add-on gives RealDx, which serves physician offices and clinics in 17 states, a cash-pay dental product line next to its reimbursed UTI, STI and respiratory testing. (Link)
  14. Thompson Street Capital-Backed Savillex Completes Carve-Out of Entegris’ Life Sciences Fluid Management Business Savillex, the Eden Prairie, Minnesota high-purity fluoropolymer and single-use bioprocessing company backed by Thompson Street Capital Partners, completed its acquisition of Entegris’ (Nasdaq: ENTG) life sciences fluid management business. The business includes Aramus and PE bioprocess bags, single-use assemblies and components. The carve-out deepens Savillex’s position with biopharma and cell and gene therapy manufacturers, and lets Entegris focus on semiconductor materials. It follows Savillex’s 2024 acquisition of Optimum Processing. Sidley advised Savillex. (Link)
  15. Sopris Capital Merges the Blackford Analysis Imaging-AI Platform, Carved Out of Bayer, into Portfolio Company Azra AI Azra AI said on October 20 that it had completed the acquisition of Blackford Analysis from Sopris Capital. Sopris had carved Blackford out of Bayer earlier in the month. Blackford’s vendor-neutral orchestration platform gives radiology departments access to more than 130 imaging-AI applications from 45+ vendors. Azra identifies patients with cancer and other complex conditions and coordinates their follow-up care. Putting the two together connects the imaging finding to the care pathway that follows it. (Link)
  16. Pacific Lake Partners-Backed Vitana Pediatric & Orthodontic Partners Acquires Louisiana’s Hollis Orthodontics, Its Fifth Deal of 2026 Vitana Pediatric & Orthodontic Partners, a dentist-led partnership organization backed by Pacific Lake Partners that focuses only on pediatric dental and orthodontic practices, bought Hollis Orthodontics in Prairieville, Louisiana, outside Baton Rouge. The practice is led by Dr. Bryan Hollis. Vitana now supports practices in Florida, Alabama, Louisiana, Pennsylvania and New Jersey. This is its fifth deal of 2026. (Link)
  17. DuneGlass Capital-Launched Aviva Aesthetics Enters Florida Through a Partnership with Allenby Cosmetic Dermatology Aviva Aesthetics, the founder-led medical aesthetics network that DuneGlass Capital launched, partnered with Allenby Cosmetic Dermatology, the practice of cosmetic dermatologist Dr. Janet Allenby. It is Aviva’s first Florida location, about seven weeks after the Perfect Skin Center partnership took the platform to 20 sites. Aviva markets its “Entrepreneur Equity” model to founders who have turned down traditional private equity MSO structures: founders keep decision-making authority and financial upside. (Link)
  18. Redesign Health and Sheba Medical Center’s ARC Global Merge in an Approximately $2 Billion Combination to Build an End-to-End Health System Innovation Platform Redesign Health, the venture and applied technology firm that has launched more than 60 healthcare companies, is merging with ARC Global, the innovation arm of Israel’s Sheba Medical Center. The combined company is valued at about $2 billion, according to a source familiar with the deal. The parties have also agreed to buy AVIA, the health-system digital technology advisory firm. Brett Shaheen will be CEO; Stephen Klasko, M.D., will chair the board; and ARC founder Eyal Zimlichman, M.D., will become vice chair. The idea is to put engineering, AI and capital inside health systems so clinician-originated ideas can become products and companies that scale across a network of more than 100 systems. (Link)
  19. Horizon Mutual Holdings, parent of Horizon Blue Cross Blue Shield of New Jersey, has entered an agreement to acquire Summit Health New Jersey, including its New Jersey CityMD urgent care centers, in a transaction reported at more than $1 billion. Horizon confirmed the agreement, which is subject to regulatory review and could close by year-end. Summit Health is one of New Jersey’s largest multispecialty physician networks; the New Jersey portion includes primary, specialty and 39 CityMD urgent care sites. It is Horizon’s largest deal since its 2022 conversion to a nonprofit mutual holding company. Horizon said the acquisition is meant to preserve access, improve quality and affordability for members, and support continued independence of Summit’s physicians. (Link)
  20. Alcon Acquires Rhode Island’s Neurotech Pharmaceuticals for $550 Million Plus Milestones, Picking Up ENCELTO, the Only FDA-Approved MacTel Type 2 Therapy Alcon completed the acquisition of Neurotech Pharmaceuticals on October 20 for $550 million upfront, plus possible contingent payments tied to commercial milestones. The deal brings in ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy implant approved in March 2025 and the only FDA-approved treatment for macular telangiectasia type 2. Neurotech estimates there are about 25,000 MacTel patients in the U.S., with 2,000 to 3,000 new diagnoses each year. Alcon expects the deal to modestly add to sales growth and slightly reduce core EPS in 2027, then add to EPS after that. (Link)
  21. Labcorp Agrees to Buy Myriad Genetics’ Prenatal Health Testing Business for $210 Million in Cash as Myriad Narrows Its Focus to Oncology Labcorp (NYSE: LH) signed a definitive agreement to buy Myriad Genetics’ (NASDAQ: MYGN) Prenatal Health testing business, including the Prequel, Foresight, SneakPeek and FirstGene tests, for $210 million in cash plus inventory value at closing. Labcorp expects about $160 million of first-year revenue, slight accretion to adjusted EPS in year one, and average diagnostics-segment margins by the end of year two. The carve-out comes out of Myriad’s strategic review, after prenatal revenue fell about 16% in the first half of 2026. It follows closely on Labcorp’s $722 million BioReference deal. (Link)
  22. Risant Health has signed a definitive agreement to acquire INTEGRIS Health, Oklahoma’s largest nonprofit health system, pending regulatory approvals. INTEGRIS Health would become Risant’s third member system after Geisinger and Cone Health. Headquartered in Oklahoma City, INTEGRIS operates roughly 20 acute and specialty hospitals and the state’s largest physician network, employing about 13,000 people. It will keep its name, medical staff, brand and leadership. Risant, backed by Kaiser Permanente, is focused on value-based care; INTEGRIS leadership pointed to access to additional capital, technology including Epic, and clinical tools that the system could not scale on its own. (Link)
  23. Bolt Biotherapeutics, Inc. (NASD: BOLT) has completed the acquisition of Prana Therapies, Inc. in a stock-for-stock reverse merger concurrent with a $120 million private placement. The sign-and-close reverse merger exchanges Prana equity for Bolt common stock and Series D non-voting convertible preferred stock. A concurrent financing raises $120 million in upfront gross proceeds from the purchase of Series D preferred, with up to an additional $60 million available if accompanying warrants are exercised. Investors include Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Eventide Asset Management, Casdin Capital and Soleus Capital. The combination focuses on Prana’s INSPIRE platform and lead bispecific antibody PRA-216 (IL-4Rα/TSLP). Proceeds are expected to fund operations into 2028. Sheila Gujrathi, M.D., former Prana CEO, joins as chief strategy officer and board member. (Link)
  24. OpenAI Acquires a16z-, 8VC- and Insight-Backed Orchestra Bio to Bring Agentic Drug-Program Management into Its Rosalind Life Sciences Suite OpenAI acquired San Francisco-based Orchestra Bio on October 20. Orchestra’s AI agents help biopharma teams coordinate drug development programs — they monitor studies, track timelines and flag delays that can spread across a program. Orchestra came out of stealth in 2025 with about $20 million from investors including Andreessen Horowitz, 8VC and Insight Partners. Its team and technology will be folded into Rosalind, OpenAI’s life sciences offering, which already has pharma partners such as Moderna and Novo Nordisk. (Link)
  25. Hackensack Meridian Health Signs a Definitive Agreement to Acquire Hunterdon Health, Committing $230 Million to the Central New Jersey System Hackensack Meridian Health, New Jersey’s largest health system, signed a definitive agreement to acquire Hunterdon Health. Hunterdon is anchored by the 184-bed Hunterdon Medical Center teaching hospital and has more than 30 medical practices. HMH committed $230 million in investment, and the deal would bring it to 19 hospitals. No closing timeline was given. (Link)
  26. Beacon Biosignals Acquires Snap Diagnostics to Expand EEG-Enabled Home Sleep Testing Nationwide Beacon Biosignals, an AI-powered precision neurotechnology company, has acquired Snap Diagnostics, a national home sleep testing provider. Snap operates as a Medicare-registered Independent Diagnostic Testing Facility accredited by The Joint Commission and serves patients in all 50 states with end-to-end shipping, scoring and interpretation. The acquisition more than doubles Beacon’s patient reach and gives it a channel to bring its FDA-cleared EEG headband technology into primary care, telehealth and specialty settings starting in 2027. (Link)
  27. CentraCare and Stellis Health Announce Plans to Integrate, with Completion Targeted for January 1, 2027 CentraCare, the integrated nonprofit health system serving Central, Southwest and West Central Minnesota, and Stellis Health, a physician-owned medical group with more than 60 providers in Wright County, have announced plans for Stellis to become part of CentraCare. The combination builds on a longstanding partnership that already includes a shared Epic electronic medical record and collaboration at CentraCare – Monticello. Stellis shareholders have voted to proceed. (Link)
  28. Further Acquires Welbi to Combine Senior Living Sales AI with Resident Experience Management Further, the Charleston-based AI platform for senior living sales and marketing, has acquired Ottawa-based Welbi, a resident experience platform. Together they reach more than 8,000 senior living communities. Further’s suite (ProspectAI, SalesAI, ResidentAI, OpsAI) helps operators attract and convert prospects; Welbi helps communities personalize daily programming and track engagement. Welbi founder and CEO Elizabeth Audette-Bourdeau will continue to lead Welbi’s operations. (Link)
  29. Vimian Group Expands Its Veterinary Surgical Offering Through the Acquisition of Norfolk Medical Products Vimian Group AB (publ), the Stockholm-based animal health company, has signed an agreement to buy Norfolk Medical Products, a family-owned U.S. provider of implants and consumables for veterinary soft-tissue surgery. Norfolk, founded in 1981, does about $6.9 million in revenue and specializes in vascular access ports and related implantable solutions. The deal is Vimian’s first move into specialized soft-tissue surgery and is expected to have a marginal impact on 2026 earnings. (Link)

Venture Deals and Other

  1. Star Therapeutics has raised $200 million in private financing to advance its preclinical pipeline of novel biologics after prior exits of subsidiary assets. The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  2. OpenAI Startup Fund and Founders Fund Co-Lead a $45 Million Round for Coherence Neuro’s AI-Enabled Brain Tumor Implant The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  3. FirstMark Capital Leads a $40 Million Series A for Baba, with CVS Health Ventures Joining, to Build AI Care Teams for Medicare and Medicaid Members New York-based Baba, an applied AI company working on the Medicare and Medicaid experience, raised a $40 million Series A led by FirstMark Capital. CVS Health Ventures and Valtruis joined, and General Catalyst, Genius Ventures and Ground Up Ventures returned. The funding will expand Baba’s clinical care teams, advance its AI research and grow its health plan partnerships. (Link)
  4. Healthleap has raised $38 million in seed and Series A funding to expand its AI platform that flags at-risk hospital patients from electronic medical records. The total comprises an $8 million seed round co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures. Founded in 2022 by siblings Jemima and Josiah Meyer, the South African-origin company analyzes clinical notes, labs, vitals and medication records to surface risk scores for conditions such as malnutrition and delirium. It is used in more than 50 hospitals including Penn Medicine, Cedars-Sinai, Houston Methodist and Emory Healthcare. (Link)
  5. Allumia Ventures Leads a $10 Million Series A for Home-Based Lung Disease Telehealth Provider Kivo Health Kivo Health, a telehealth provider of virtual pulmonary rehabilitation and care for COPD and other chronic lung diseases, raised a $10 million Series A led by Allumia Ventures, according to Axios Pro. Home-based respiratory care is an area health plans and risk-bearing providers have been looking at for value-based contracts. (Link)
  6. Zai Lab Limited (NASD: ZLAB; HKEX: 9688) has entered a securities purchase agreement for a $250 million PIPE financing of American Depositary Shares. Zai Lab agreed to sell 11,340,000 ADSs at $22.04 each, for expected gross proceeds of about $250 million before fees. The financing is led by TCGX and includes participation from abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Wellington Management and others. Net proceeds are intended primarily to support continued global development of zocilurtatug pelitecan (zoci), the company’s DLL3-targeting antibody-drug conjugate. Leerink Partners is the exclusive placement agent. (Link)

IPOs:

  1. Lycia Therapeutics Prices Upsized $317.5 Million Initial Public Offering at $18 per Share Lycia Therapeutics, Inc. (NASD: LYCA), a clinical-stage biotechnology company developing LYTAC degraders of disease-causing extracellular proteins, priced its upsized IPO of 17,640,000 shares at $18.00 per share, for expected gross proceeds of about $317.5 million. The company had originally marketed 14.7 million shares at $16–$18. Lead programs include LCA-0061 (an IgE degrader for food allergy) and LCA-0321 (an autoantibody degrader for Graves’ disease). Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint book-running managers. The platform is based on work by Nobel laureate Carolyn Bertozzi. (Link)
  2. Anthropic Files Public S-1 for Nasdaq IPO Under Ticker (NASD:ANT) Anthropic, the AI lab behind the Claude model family, has filed a public S-1 registration statement with the SEC for an initial public offering on Nasdaq under the ticker ANT. The Claude maker is targeting a valuation of $1.5–2 trillion, which would make it one of the largest IPOs on record and roughly double the $965 billion mark from its May funding round. First-half 2026 revenue was $16.3 billion, against about $4.6 billion for all of 2025. Third-quarter revenue reached $16.8 billion, up about 45% sequentially, and the company said it was profitable on an adjusted basis. The $80.7 billion first-half net loss is largely a non-cash charge tied to the rising valuation. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 12th, 2026

LECO_Weekly-Healthcare-News_10-12-2026Download

Healthcare Weekly News and Deals – Oct 12th, 2026

  1. Clayton, Dubilier & Rice and McKesson (NYSE: MCK) have agreed to take infusion provider Option Care Health (NASD: OPCH) private in a $5.8 billion deal at $32.05 per share, with CD&R holding 51% and McKesson about 49%. Clayton, Dubilier & Rice and McKesson (MCK) will acquire Option Care Health (OPCH), the largest independent U.S. provider of home and alternate-site infusion services, for $32.05 per share, a 37% premium to its prior close, valuing the deal at $5.8 billion. McKesson plans to invest about $1.4 billion for its roughly 49% interest, and the agreement sets out a framework for McKesson to later buy CD&R’s stake. Option Care treats more than 308,000 patients a year across all 50 states and generated over $5.6 billion of 2025 net revenue. McKesson framed the investment around its specialty and complex-therapy strategy. Closing is expected in the first half of 2027. (Link)
  2. STERIS (NYSE: STE) has agreed to acquire Xodus Medical for $2.1 billion at closing, or about $1.8 billion net of expected tax benefits, plus an earnout of up to $150 million. Xodus was founded in the early 1990s and is based in New Kensington, Pennsylvania, outside Pittsburgh. It builds devices meant to keep patients and operating-room staff safer during surgery. The core product is the Pink Pad, a positioning system used to hold patients in place and reduce pressure injury. A later version combines that pad with underbody warming to address perioperative hypothermia. Hospitals buy the line as a consumable rather than as capital equipment. STERIS already sells infection-prevention products and surgical supplies, so the tuck-in adds a branded safety line. Xodus is expected to do about $245 million of revenue in 2026, with adjusted EBIT of about $135 million. STERIS plans to fund the purchase mainly with debt. Completion is aimed at December 31, 2026 and still needs regulatory sign-off. (Link)
  3. Viatris (NASDAQ: VTRS) has agreed to acquire Pacira BioSciences (NASDAQ: PCRX) for $36.50 a share in cash, or $1.65 billion. Pacira’s commercial book is built on two non-opioid pain drugs. EXPAREL is a liposomal bupivacaine injection used for local pain control after surgery. ZILRETTA is an extended-release steroid injected into the knee for osteoarthritis. The two products booked about $692 million in 2025, and Pacira reported full-year revenue of about $726 million. Both are already on the market, so this is a product acquisition rather than a pipeline bet. The cash price is a 45 percent premium to the prior close. Viatris, based in Pittsburgh, has been shifting from generics and established brands toward a smaller innovative-medicines franchise, and has an oral meloxicam under FDA review with a December 27 decision date. Generic erosion of EXPAREL is expected to begin in early 2030 under earlier patent settlements. Close is expected by the end of 2026. (Link)
  4. BDT & MSD Partners has agreed to acquire a majority stake in Sunrise Senior Living from the Public Sector Pension Investment Board (PSP Investments) in a deal reportedly valuing the operator above $1 billion, with Sunrise management owning the balance. Funds affiliated with BDT & MSD Partners signed a definitive agreement to buy Sunrise Senior Living from Canada’s PSP Investments, which first invested in 2014 and became sole owner in 2023. CEO Jack Callison Jr. and senior executives will invest significant personal capital alongside BDT & MSD’s majority position. Press reports cite a valuation above $1 billion. Sunrise operates more than 230 communities in North America, serving over 22,000 residents and has a pipeline of 50-plus communities with expected development costs of about $7.5 billion. (Link)
  5. Healthcare Services Group (NASD: HCSG) has acquired Mansfield, Massachusetts-based dining and hospitality manager NEXDINE Hospitality for $93.5 million upfront plus a performance-based earnout. Healthcare Services Group (HCSG), the Bensalem, Pennsylvania-based provider of housekeeping, laundry and dining services to healthcare facilities, acquired privately held NEXDINE Hospitality, announced on October 7, 2026, paying $93.5 million upfront in cash on hand, with additional consideration if NEXDINE meets certain performance targets. NEXDINE, a dining and hospitality service management company with a strong senior living presence, is expected to contribute more than $150 million of annual revenue, implying an upfront price of about 0.6x sales. It will operate as a wholly owned subsidiary under its own brand, led by founder and CEO David Lanci. HCSG framed the deal as an expansion into senior living and hospitality-driven care markets. (Link)
  6. Tiffin, Ohio-based Surgence Innovations has secured a $15 million investment from private funds advised by Ohio investor The O.H.I.O. Fund, spinning out as an independent company from Ohio distributor Concordance Healthcare Solutions. Surgence, a healthcare supply chain platform built on the Palantir (NASD: PLTR) Foundry operating system, announced the $15 million on October 6, 2026, with the capital establishing it as an independent corporation. It was incubated under Tiffin, Ohio-based Concordance Healthcare Solutions, an independent distributor with 15 distribution centers licensed in 48 states, which keeps a significant ownership stake and remains a strategic and commercial partner. The O.H.I.O. Fund invests exclusively alongside businesses that call Ohio home; partner Mike Venerable framed the deal as long-term capital supporting Ohio’s healthcare leadership. Proceeds will fund product development, customer growth, hiring and innovation across the healthcare supply chain. (Link)
  7. Standard BioTools (NASDAQ: LAB) has agreed to sell its Microfluidics business to ARCHIMED. The unit being carved out makes integrated fluidic circuits, small chips that run hundreds to thousands of reactions from a single sample. Research labs use them for genotyping, gene-expression work and library preparation ahead of next-generation sequencing. The technology came in through Fluidigm, the predecessor company, and has been cited in thousands of genomics papers. The buyer is a healthcare-only private equity firm founded in 2014 and based in Lyon, France. It invests in life-science tools, diagnostics and medtech on both sides of the Atlantic, and is taking the unit as a standalone business rather than folding it into an operating company. The Boston seller has been pruning a portfolio assembled through earlier combinations. Closing is expected in about 30 days. No price was given. (Link)
  8. Spectrum Equity has made a strategic growth investment in healthcare supply chain data provider Symmetric Health Solutions, the company’s first institutional capital. Spectrum Equity, a growth equity firm founded in 1994 that focuses on AI, software and data businesses, backed Symmetric in a deal announced on October 6, 2026; the size was not disclosed. Founded in 2018 by former Accenture supply chain consultants and Carnegie Mellon alumni, Symmetric reached profitability without outside capital and maintains a database of nearly 20 million healthcare items, each with up to 1,800 metadata attributes, used by more than 850 hospitals. Managing Director Michael Radonich said the company has become the system of record for supply data at several of the largest U.S. health systems. Proceeds fund go-to-market, customer success and new products, including a supply chain control tower. (Link)
  9. FFL Partners has made a growth investment in Nashville-based Ally Technical, the healthcare technology management company formerly known as Althea US. FFL Partners backed Ally Technical alongside the company’s rebrand, in a deal announced on October 6, 2026 with undisclosed terms. Ally Technical provides service, parts, board-level and depot repair, technical support and training for medical equipment from major manufacturers, built on deep expertise in contrast injectors, and supports a large installed base of aging devices across the U.S. FFL partner Karen Winterhof said providers are increasingly turning to independent service organizations for cost-efficient maintenance and parts. The investment came out of FFL’s SEED sector-exploration strategy, and the partners plan organic growth plus M&A, including expansion into new device modalities and under-penetrated markets. CEO Dan Siler continues to lead. (Link)
  10. Harbor Health has agreed to acquire 27 Village Medical clinics in the Houston area. The sites are primary-care offices spread across Harris, Montgomery, Fort Bend and Brazoria counties. They had been run as part of a larger clinic network. The buyer is a Texas primary-care and insurance company that already pairs offices with its own plans in Austin, Dallas, San Antonio and El Paso. This is the fifth market on that model. It bought 32 clinics from the same seller in those other cities in 2025. Plans carry no deductible, and referred specialty care is covered at no cost when one of its clinicians makes the referral. Individual and family enrollment for the new market opens November 1, with coverage effective January 1. No price was disclosed, and the release does not break out patient volume or revenue for the sites. (Link)
  11. Bambu Capital-owned Lemonaid Health has acquired the fitness and longevity business of Dr. B, the telehealth company founded by Zocdoc founder Cyrus Massoumi. Lemonaid Health, the digital pharmacy and telehealth platform owned by Bambu Capital, bought Dr. B’s fitness and longevity business on October 5, 2026, including its national fitness-brand partnerships and longevity membership base; terms were not disclosed. Dr. B built an early scaled gym-as-clinic model in which members can use pre-tax HSA/FSA dollars for gym memberships through letters of medical necessity. The deal gives Lemonaid a gym partner network reaching more than 5 million members and a metabolic-health patient base. Bambu Managing Partner Dylan Runne said it fits the thesis behind Bambu’s Lemonaid purchase: pairing a licensed clinical and pharmacy engine with partners that own the customer relationship. (Link)
  12. Varsity Healthcare Partners-backed United Aesthetics Alliance has acquired St. Louis-based Parkcrest Plastic Surgery and the Aesthetics Center. United Aesthetics Alliance, a physician practice management holding company sponsored by lower middle-market healthcare private equity firm Varsity Healthcare Partners since 2023, completed the acquisition, reported on October 7, 2026; terms were not disclosed. Founded in 2001, Parkcrest provides plastic surgery and medical spa services and is led by co-founding board-certified plastic surgeons Dr. David Caplin and Dr. Patricia McGuire. The deal is the platform’s first acquisition of 2026 and establishes its footprint in Missouri, in line with its strategy of consolidating market-leading plastic surgery practices and affiliated medical aesthetic providers. Parkcrest will keep operating from its current St. Louis location under its existing brand. (Link)
  13. GreyLion Capital-backed Trifecta Collective has acquired the Medical Spa Show from the American Med Spa Association (AmSpa) and entered a long-term partnership with the association. Trifecta Collective, a multi-sector trade show organizer founded in 2021 by industry veteran Rick McConnell and supported by financial partner GreyLion Capital, announced the acquisition on October 6, 2026; terms were not disclosed. Launched by AmSpa in 2018, the Medical Spa Show has drawn nearly 10,000 attendees from more than 5,200 practices and hosted over 750 exhibiting brands; its 10th edition at Wynn Las Vegas in April 2027 is expected to attract more than 3,500 medical aesthetics professionals. McConnell called medical aesthetics one of the fastest-growing segments in healthcare and wellness. AmSpa stays involved under the partnership, and the current show team remains. (Link)
  14. 1 Natural Way, based in Maumee, Ohio, has acquired New England Surgical. The buyer was started in 2014 by Ryan Wright to ship insurance-covered breast pumps and related maternal products. It now works with major carriers in all 50 states, carries pumps from more than a dozen manufacturers, and runs an in-house program with certified lactation consultants. The target, in Fall River, Massachusetts, has sold medical supplies and home equipment across Massachusetts and Rhode Island for more than four decades. What is being bought is the regional payor contracts, not a new product line. Those contracts cover insured patients the Ohio company could not previously bill. The buyer said the add-on widens the set of mothers it can serve at little or no out-of-pocket cost. No price was disclosed. (Link)
  15. RiverGlade Capital has formed Sentinel Care Group, a healthcare franchise platform led by former Right at Home CEO Brian Petranick. Chicago-based RiverGlade Capital, a private equity firm founded in 2017 that makes control and select minority investments in lower middle-market healthcare companies, launched Sentinel Care Group on October 8, 2026. According to PE Hub, the platform will acquire and partner with existing businesses and emerging franchisors, and develop new franchise concepts from scratch. Petranick spent more than two decades at Right at Home, helping grow it from a single Omaha location into an international in-home care franchise with more than 650 territories, and served as president and CEO until 2022. RiverGlade’s franchise experience includes home care franchisor Home Helpers Home Care, acquired in 2021. Capital commitments were not disclosed. (Link)
  16. Emergence, the permanent-capital enterprise backed by The Pritzker Organization, has acquired Charlotte, North Carolina-based patient-reported outcomes software company Clinect Healthcare. Emergence, which provides long-term capital and operating support to software and technology-enabled businesses rather than following a hold-and-exit model, announced the acquisition of Clinect Healthcare on October 8, 2026; terms were not disclosed. Founded in 2012 by CEO Brian Schmitz, Clinect runs an Outcomes Intelligence Platform combining digital intake, patient-reported outcomes, patient experience and reputation management tools, with more than 600 validated outcome measures integrated into practice management and EHR systems. Emergence Operating Partner David Henriksen cited the opportunity as payers demand proof of care results. The deal adds to Emergence’s healthcare software roster after its November 2025 purchase of MedEvolve, and funds data science, AI and interoperability investment. (Link)
  17. Sienna Senior Living (TSX: SIA) has agreed to acquire Brighton Retirement & Active Living, a 165-suite seniors’ residence in Brighton, Ontario, for approximately C$73.8 million. Sienna Senior Living (SIA), the Markham, Ontario-based seniors’ housing owner and operator, signed an agreement on October 8, 2026 to buy Brighton Retirement & Active Living, about 150 km east of Toronto, for a gross price of roughly C$73.8 million, or C$447,000 per suite. Terms add C$1.5 million of income support for the lease-up of the seniors’ apartments and commercial units, plus a C$5.0 million earnout tied to financial targets. The property has 124 retirement suites opened in 2024 and about 95% occupied, 41 seniors’ apartments opened in 2025 and five commercial units. Sienna is funding the deal from cash and credit facilities, with closing expected in Q4 2026. (Link)
  18. Grovecourt Capital-backed Guide Architecture has acquired medical equipment planning firm MAIA as an add-on to its Dallas-based healthcare design platform. West Palm Beach, Florida-based Grovecourt Capital, a lower middle-market investor in founder-led business services and healthcare services companies, added MAIA to portfolio company Guide Architecture in a deal reported on October 8, 2026; terms were not disclosed. MAIA is a 25-person healthcare consulting firm providing medical equipment planning, procurement support, BIM and Revit services, inventory assessment and implementation support. Guide, founded in Dallas in 2014, plans and designs hospitals, outpatient centers, behavioral health facilities and medical office buildings for health systems nationwide. Grovecourt invested in Guide in April 2026, with existing leadership remaining significant owners, and set out a strategy of acquisitions that deepen healthcare expertise and client relationships. (Link)
  19. Oak Hill Capital-backed Petauri has acquired health economics and market access consultancy Franklin Pharmaceutical Consulting. Nashville-based Petauri, the life sciences commercialization platform Oak Hill Capital founded with CEO Dan Renick, announced the acquisition of Franklin Pharmaceutical Consulting (FPC) on October 8, 2026; terms were not disclosed. Oak Hill is committing more than $250 million of equity to Petauri from its latest fund, OHCP VI, and the platform has previously bought The Kinetix Group, the FORCE Communications agencies, Mtech Access, Delta Hat, the Brightly Network agencies, Formulary Insights and Artia Solutions. FPC provides health economics and outcomes research, real-world evidence strategy, payer value communications and dossiers. It folds into Petauri Evidence, with founder Meg Franklin becoming President of Petauri Evidence US. (Link)
  20. Lee Equity Partners-backed Marwood Group has acquired Ronan Healthcare Compliance, expanding its compliance advisory capabilities. New York-based Marwood Group, a healthcare advisory and consulting firm that recently took a strategic investment from Lee Equity Partners, acquired Ronan Healthcare Compliance in a deal announced October 12, 2026. Ronan, founded by Ross and Susan Ronan, provides outsourced compliance officer services, risk assessments, buy-side and sell-side diligence, and program development to more than 60 healthcare organizations across 21 specialties. The full Ronan team joins Marwood, with Ross Ronan becoming Managing Director and Head of Compliance Services. Terms were not disclosed. Bailey & Co advised Ronan. (Link)

Venture Deals and Other

  1. Andreessen Horowitz has led a $120 million Series B in San Francisco-based General Medicine, joined by Matrix, VXI Capital, Eli Lilly (NYSE: LLY), BoxGroup and Ohio-based Mercy Health through Granger Management. a16z General Partner Vineeta Agarwala led the round, announced on October 6, 2026, which lifts General Medicine’s total funding to $152 million. Eli Lilly (LLY) and Cincinnati, Ohio-based Mercy Health, investing through Granger Management, join as strategic backers alongside Matrix, VXI Capital and BoxGroup. Founded in 2023 and launched nationwide in May 2025, General Medicine runs a healthcare store listing more than 2,900 medications, labs, telehealth visits, specialist e-consults and procedures with upfront insurance and cash prices. It has signed up hundreds of thousands of customers with an average NPS of 80. Former Matrix General Partner TJ Parker became full-time CEO in October. Proceeds expand the store into new care categories. (Link)
  2. Dr. Patrick Soon-Shiong’s NantWorks has led a $75 million Series B in San Francisco-based Multiply Labs, joined by AstraZeneca (NASD: AZN), Lingotto, Teradyne (NASD: TER), Strange Ventures, Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. NantWorks led the round, announced on October 6, 2026, which takes Multiply Labs’ total funding above $100 million since its 2016 founding; valuation was not disclosed. New investors AstraZeneca (AZN), Lingotto, Teradyne (TER) and Strange Ventures joined returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. AstraZeneca is also a customer, underscoring the strategic weight of the cap table. Multiply Labs builds robotic clusters that automate manual steps in biologics manufacturing, initially for cell and gene therapies and now antibodies, viral vectors and mRNA, with systems owned and run in-house by drugmakers. Proceeds fund manufacturing capacity, product development and engineering, regulatory and commercial hiring. (Link)
  3. Sequoia Capital, First Round Capital and Hummingbird Ventures have backed clinical AI company Healthleap in $38 million of combined seed and Series A funding. Healthleap disclosed the $38 million on October 8, 2026, with Sequoia partner Alfred Lin and First Round co-founder Josh Kopelman both endorsing the investment. Founded in 2022 by siblings Josiah and Jemima Meyer, the company continuously analyzes patient records, including notes, labs, vitals and orders, to flag undiagnosed conditions and push risk scores into EHR workflows. It started with disease-related malnutrition, which costs the U.S. system up to $58 billion annually; one Penn Medicine hospital attributed $23.8 million a year in reimbursement and length-of-stay benefits to the platform. Proceeds fund expansion to more than 40 conditions and hiring to reach hundreds of hospitals. (Link)
  4. The Florida Opportunity Fund and Tampa General Hospital’s TGH Ventures have co-led a $35 million growth equity investment in Spark Pediatrics, with Town Hall Ventures, UPMC Enterprises and Memorial Hermann participating. Spark Pediatrics, which operates Prescribed Pediatric Extended Care centers for children with medical complexities, including a Clearwater, Florida location, announced the $35 million equity investment on October 9, 2026. The Florida Opportunity Fund and TGH Ventures led, with continued participation from existing investor Town Hall Ventures and all of Spark’s existing strategic partners, including UPMC Enterprises and Memorial Hermann. The health system backers give Spark strategic relationships across Florida, Pennsylvania and Texas. Proceeds will support Spark’s leading presence in Florida, growth in Texas and expansion into Pennsylvania, Louisiana and other new states. Valuation and round designation were not disclosed. (Link)
  5. Oak HC/FT has led a $31 million Series A in San Francisco-based Vitalize, joined by Norwest, .406 Ventures, Constellation Ventures, Y Combinator, Rock Health Capital and MemorialCare Innovation Fund. Oak HC/FT partner Vig Chandramouli led the round, announced on October 6, 2026, with health system venture arm MemorialCare Innovation Fund participating as a strategic investor. Vitalize sells an AI-native platform that automates scheduling and forecasts demand to coordinate staffing and bed capacity across health systems, integrating with EMR and time-and-payroll systems. It manages millions of shifts a week across dozens of enterprise health systems; St. Luke’s Health reported a 54% cut in premium labor spend within 12 weeks. Oak HC/FT, with more than $7 billion under management, views hospital labor, a nearly $1 trillion cost line, as an underpenetrated software market. Proceeds fund growth, deployment and throughput AI. (Link)
  6. Maveron has led a $25 million Series A in New York-based oral care membership company Wally, joined by Bling Capital and angel investors including Hims & Hers Health (NYSE: HIMS) co-founder Jack Abraham. Maveron partner Jason Stoffer backed Wally’s model of replacing insurance-driven dentistry with a $249 annual membership covering unlimited cleanings, AI-supported diagnostics, exams and whitening; the round was announced on October 7, 2026. Bling Capital and angels including Jack Abraham participated. Wally has passed 50,000 members who visit three times a year, reports a 97% hygienist retention rate and operates 15 locations in co-working spaces across New York City, Philadelphia, Jersey City and Chicago. It also announced a strategic partnership with EMS Dental. Proceeds fund expansion from 15 to 100 locations by end-2027, including Washington DC, Atlanta, Austin and Miami. (Link)
  7. F-Prime has led a $20 million Series A in Allentown, Pennsylvania-based AblePay Health, with participation from A1 Health Ventures and .406 Ventures. F-Prime principal Nikhil Marathe led the round, announced on October 7, 2026, as AblePay enters its second decade. Chicago-based A1 Health Ventures, whose limited partners are health systems operating more than 110 hospitals, and Boston’s .406 Ventures, with over $1.3 billion under management, joined. Founded in 2016, AblePay integrates with providers to guarantee non-recourse payment on an accelerated timeline while offering enrolled patients flexible payment options, savings on out-of-pocket costs and free billing advocacy. The company cites $591 billion of U.S. out-of-pocket healthcare spending in 2025, up 6%. Proceeds will expand its reach to more health systems and deepen its technology platform. (Link)
  8. Norrsken VC has led a $20 million Series A in Paris- and New York-based AI medical receptionist company Vocca, joined by Heal Capital, Speedinvest and firstminute capital. The round, announced on October 6, 2026, lifts Vocca’s total funding to $25 million about a year after its previous raise; valuation was not disclosed. Founded in July 2024 by Eliott Hoffenberg and Hugo Danet, Vocca builds specialty-specific AI agents that answer patient calls, book and reschedule appointments and handle routine requests for medical practices. It has grown from 2,000 to 15,000 practitioners in a year across the U.S. and Europe and now handles more than one million patient conversations a month. Proceeds will deepen its U.S. presence through its New York office, add specialties and channels beyond voice, and fund about 40 hires. (Link)
  9. NFX has led a $7 million seed round in Altro Health, with Founder Collective and Primetime Partners’ Abby Miller Levy participating. NFX general partner James Currier said the firm backed Altro, formerly Lyv Health, for its position in a large new consumer category with no clear leader; the round was announced on October 6, 2026. Altro operates a Shopify-style platform that lets personal trainers, gyms and medspas offer clinician-prescribed peptides, GLP-1s, hormone therapy and lab testing under their own brands, with a board-certified clinical team supervising each service and products sourced from licensed 503A and 503B pharmacies. More than 500 businesses already use the platform, with plans starting at $319 a month. Proceeds fund product development, hiring, and sales and marketing. (Link)
  10. Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures have backed New York-based deprescribing platform Outro in $7 million of pre-seed and seed funding. Outro disclosed the $7 million across pre-seed and seed rounds on October 8, 2026, with participation from Listen Ventures, Cake Ventures, Jason Calacanis’ LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures, among others. Co-founded by CEO Brandon Goode and psychiatric deprescribing researcher Dr. Mark Horowitz, Outro runs a virtual clinic that helps patients taper off antidepressants through personalized plans, monitoring and clinician support, and is available in 14 states. It cites roughly 50 million Americans taking antidepressants. Proceeds expand the clinician network, apply AI to tapering workflows and extend the model into other medication classes. (Link)

Market Rumors / IPO

  1. Solventum (NYSE: SOLV) is seeking bids for its Health Information Systems unit, pitched at a $5.5 billion to $7 billion valuation. Solventum, the medical products and technology company spun out of 3M, is collecting initial bids for its Health Information Systems division, according to reports on October 12, 2026. The unit provides hospitals and health systems with medical coding, billing, documentation and revenue cycle management software and generated about $1.4 billion of sales last year. Solventum announced plans to separate the business in August 2026 as it focuses on medsurg and dental. Shares slipped after the report. No buyer has been named, and a sale or spin remains possible. (Link)
  2. Bambusa Therapeutics has filed a Form S-1 for a proposed Nasdaq IPO under the symbol B BTX.Bambusa was incorporated in Boston in March 2024. It is a clinical-stage company working on long-acting bispecific antibodies for immunology and inflammation. BBT001 targets IL-4Rα and IL-31 for atopic dermatitis and chronic spontaneous urticaria. BBT002 targets IL-4Rα and IL-5 for COPD, nasal polyps and asthma. Two earlier programs are still preclinical. Private investors including RA Capital, BVF Partners, ATHOS and Dawn Biopharma have put in about $136 million. Cash was $71.5 million at June 30. The filing does not set a share count or a price. Named underwriters include BofA Securities, Evercore, UBS and Cantor. (Link)

CLICK HERE to sign up
for all news and updates